Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA

Watchlist Manager
Sun Pharmaceutical Industries Ltd Logo
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Watchlist
Price: 1 795.3 INR 0.86% Market Closed
Market Cap: 4.3T INR
Have any thoughts about
Sun Pharmaceutical Industries Ltd?
Write Note

Sun Pharmaceutical Industries Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sun Pharmaceutical Industries Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Gross Profit
â‚ą398.2B
CAGR 3-Years
14%
CAGR 5-Years
12%
CAGR 10-Years
8%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Gross Profit
â‚ą205B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Gross Profit
â‚ą177.7B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
10%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Gross Profit
â‚ą144.8B
CAGR 3-Years
13%
CAGR 5-Years
11%
CAGR 10-Years
12%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Gross Profit
â‚ą84.8B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
10%
M
Mankind Pharma Ltd
NSE:MANKIND
Gross Profit
â‚ą69.4B
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sun Pharmaceutical Industries Ltd
Glance View

Market Cap
4.3T INR
Industry
Pharmaceuticals

Sun Pharmaceutical Industries Ltd. is a leading global pharmaceutical company based in India, renowned for its commitment to producing high-quality generic and specialty medicines. Founded in 1983, Sun Pharma has evolved into one of the largest pharmaceutical companies in India and the fifth largest globally in the generic market. With a robust portfolio that encompasses various therapeutic areas, including cardiology, psychiatry, neurology, and oncology, the company has built a solid reputation for innovation and reliability. A strong emphasis on research and development drives Sun Pharma’s growth, helping it to continuously expand its product offerings and tap into new markets, as evidenced by its strategic acquisitions and partnerships over the years. For investors, Sun Pharmaceutical presents a compelling opportunity, underpinned by its solid financial performance and a forward-looking strategic vision. The company's extensive presence in over 150 countries combined with a diverse portfolio fuels its competitive edge in the global pharmaceutical landscape. With a solid track record of profitability and a commitment to enhancing shareholder value, Sun Pharma is well-positioned to capture growth in emerging markets and capitalize on advancements in biologics and complex generics. Moreover, the company’s focus on sustainability and ethical practices resonates in an increasingly socially conscious investment environment, making it an appealing prospect for investors looking to diversify their portfolios while supporting a responsible industry leader.

SUNPHARMA Intrinsic Value
1 046.73 INR
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Sun Pharmaceutical Industries Ltd's Gross Profit?
Gross Profit
398.2B INR

Based on the financial report for Sep 30, 2024, Sun Pharmaceutical Industries Ltd's Gross Profit amounts to 398.2B INR.

What is Sun Pharmaceutical Industries Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
8%

Over the last year, the Gross Profit growth was 12%. The average annual Gross Profit growth rates for Sun Pharmaceutical Industries Ltd have been 14% over the past three years , 12% over the past five years , and 8% over the past ten years .

Back to Top